On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar

On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar kdunleavy Fri, 08/09/2024 - 09:52